Abstract P274: FGF-23 is Associated with Left Ventricular Hypertrophy and Systolic Dysfunction among Patients with Coronary Heart Disease: The Heart and Soul Study

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Isha Agarwal ◽  
Joachim Ix ◽  
Bryan Kestenbaum ◽  
Nelson Schiller ◽  
Mary Whooley ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Left Ventricular Hypertrophy ◽  
Left Ventricular Mass ◽  
Kidney Function ◽  
Odds Ratio ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Concentric Hypertrophy ◽  
Fgf 23

Introduction: Fibroblast growth factor-23 (FGF-23) is a bone-derived phosphaturic hormone strongly associated with cardiovascular mortality and left ventricular hypertrophy among individuals with end-stage renal disease (ESRD). Whether the relationship between FGF-23 and cardiac dysfunction extends to participants without ESRD is not clearly established. Hypothesis: We tested whether FGF-23 is associated with left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF) in participants with coronary heart disease (CHD) and a broad range of kidney function in the Heart and Soul Study. Methods and Results: In cross-sectional analyses of 887 participants of the Heart and Soul Study, FGF-23 was positively associated with LVMI (2.09 g/m 2 , 95% confidence interval [CI] 0.15 to 4.03 per 1 standard-deviation [SD] higher ln FGF-23) and inversely associated with LVEF (-0.96%, CI -1.71% to -0.21%, per 1 SD higher ln FGF-23) after adjustment for age, CHD risk factors, microalbuminuria, and cystatin-based estimated glomerular filtration rate (eGFR). In multinomial logistic regression, FGF-23 was associated with an increased prevalence of concentric hypertrophy (odds ratio 1.66, CI 1.00 to 2.76, per 1 SD increase in ln FGF-23) but not eccentric hypertrophy (odds ratio 1.14, CI 0.96 to 1.36). The association between FGF-23 and concentric hypertrophy was stronger among individuals with an estimated GFR < 60 mL/min per 1.73 m 2 , and was not statistically significant among individuals with normal to mildly reduced kidney function (Figure, p interaction 0.11). Conclusion: In conclusion, FGF-23 was associated with greater left ventricular mass and concentric hypertrophy, particularly among individuals with diminished kidney function. Additional studies are necessary to determine the pathways that mediate this association.

Reduced Vital Capacity in Elderly Persons With Hypertension, Coronary Heart Disease, or Left Ventricular Hypertrophy

CHEST Journal ◽  
1995 ◽  
Vol 107 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Paul L. Enright ◽  
Richard A. Kronmal ◽  
Vivienne-Elizabeth Smith ◽  
Julius M. Gardin ◽  
Marc B. Schenker ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Vital Capacity ◽  
Left Ventricular ◽  
Elderly Persons

scholarly journals Aldosterone synthase gene polymorphism in patients with hypertension combined ischemic heart disease with in various left ventricular mass

2014 ◽  
Vol 11 (1) ◽  
pp. 16-20
Author(s):  
D A Yahontov ◽  
D A Derisheva ◽  
L F Gulyaeva
Keyword(s):  
Coronary Artery Disease ◽  
Heart Disease ◽  
Left Ventricular Hypertrophy ◽  
Left Ventricular Mass ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Aldosterone Synthase ◽  
Ventricular Mass ◽  
Artery Disease ◽  
The Relationship

Study purpose - assessment of the relationship of levels of aldosterone and natriuretic peptide plasma aldosterone synthase gene polymorphism variants in patients with coronary heart disease (CHD) in combination with arterial hypertension (AH) at different left ventricular mass.Materials and methods. The study involved 63 male with hypertension and CHD; there were 32 men with signs of left ventricular hypertrophy (LVH) and 31 men with coronary artery disease with hypertension with a normal index of left ventricular mass. Evaluated the concentrations of aldosterone and plasma natriuretic peptide (NUP) in the relationship with characteristic of aldosterone synthase gene polymorphism.Results. It is established that the genotype CYP11В2 T/С of is associated with increased levels of aldosterone and signs of left ventricular hypertrophy. The level of LVC in the signs of LVH group was 2,1 fold higher than in patients without LVH. For patients with evidence of left ventricular hypertrophy is characterized by: the genotype of CYP11В2 T/C (62,5% of cases), the identification of the T allele (1,3 times more likely than patients without evidence of LVH) and more rarely than with normal index of left ventricular mass occurs variant CYP11В2 T/Т and more rarely prevalent allele C. Conclusion. In patients with coronary artery disease and hypertension, it is reasonable to implement in practice population genetic analysis to assess the probability the formation of left ventricular hypertrophy in the early stages of the disease.

Abstract P369: Left Ventricular Hypertrophy and Coronary Heart Disease Risk Reclassification in Blacks and Whites: The Atherosclerosis Risk in Communities (ARIC) Study

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Tochi Okwuosa ◽  
Elsayed Z Soliman ◽  
Alvaro Alonso ◽  
Kim A Williams ◽  
Faye Lopez ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Risk Model ◽  
Left Ventricular ◽  
C Statistic ◽  
Framingham Risk ◽  
Ecg Score

Introduction: Left ventricular hypertrophy (LVH) is more prevalent in blacks than whites, and is a major independent predictor of coronary heart disease (CHD)/CVD survival in blacks. We evaluated the ability of LVH to predict CHD outcomes beyond traditional cardiovascular risk factors in blacks, compared with whites from a large community-based cohort. Methods: Data were analyzed on 14,489 participants (mean age 54 +/- 5.7 years, 43.5% men, and 26% black) within the ARIC cohort, with baseline (1987-1989) electrocardiograms (ECG), followed through 2009. Risk estimates for incident CHD were assessed using the 10-year Framingham Risk Score (FRS). Model 1 was the Framingham base model, while model 2 included the base model plus LVH by any of 11 traditional ECG-LVH criteria (Table). Net reclassification improvement (NRI) was calculated, and the distribution of risk was compared using model 2 vs. model 1. Results: There were 690 (4.8%) 10-year and 1515 (10.5%) 20-year CHD events. LVH defined by any criteria was associated with CHD events in the entire cohort [HR (95% CI): 1.42 (1.20-1.7)]. LVH defined by the Framingham ECG score and LV strain criteria were the criteria most associated with CHD overall. LVH by Framingham ECG score was most associated with CHD in blacks [HR (95%CI): 2.53 (1.65-3.89)], while LV strain showed the strongest association with CHD in whites [1.73 (1.18-2.56)]. No statistically significant improvement in NRI or C-statistic was observed in model 2 [C-statistic (95% CI): 0.779 (0.763-0.794), NRI = 0.006 (p = 0.41)], compared with the base model [0.777 (0.762-0.792)]; and no racial interactions were observed. Findings were unchanged when the base model was replaced with the 10 and 20-year ARIC risk model (includes diabetes) for CHD. Conclusions: In this cohort of black and white men and women, LVH (defined by ECG) was significantly associated with CHD after adjustment for FRS; but did not significantly improve CHD risk prediction beyond the FRS. No significant black-white differences in risk prediction were observed. Table. Reclassification of Coronary Heart Disease by the addition of each Criterion for Left Ventricular Hypertrophy, based on a 10-year Framingham Risk Model * Base model factors in age, gender, current smoking, diabetes, systolic blood pressure, diastolic blood pressure, HDL cholesterol and total cholesterol as separate variables. * NRI categorized as <10%, 10-20% and >20%. Abbreviations: NRI = Net Reclassification Index, IDI = Integrated Discrimination Index, HR = Hazard Ratio, CI = Confidence Interval

Relation of Blood Pressure Components to Left Ventricular Hypertrophy and Coronary Heart Disease with Aging

2004 ◽  
Vol 34 (2) ◽  
pp. 142 ◽  
Author(s):  
Jae Suk Park ◽  
Chang Gyu Park ◽  
Mi Young Park ◽  
Jae Hyoung Park ◽  
Yong Hyun Kim ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Left Ventricular
Sign in / Sign up

Export Citation Format

Share Document